# PROOF302 (NCT04197986)

> Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04197986
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: QED Therapeutics, a BridgeBio company
- Conditions: Upper Tract Urothelial Carcinomas; Urothelial Bladder Cancer
- Interventions: Infigratinib; Placebo
- Enrollment: 39
- Primary outcome: Centrally Determined Disease-free Survival (DFS)

## Commentary we found

- X threads: 18
- YouTube: 6
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=proof302-nct04197986

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04197986", "email": "<work email>"}; the inbox owner confirms by the emailed link.